Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart in Combination With TAS-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer
NCT07656038Phase 1Not yet recruiting
- Sponsor
- STCube
- Start
- Jun 2026
- Primary completion
- Jul 2028
01
Overview
Phase 1, open-label, single-arm trial of nelmastobart in colorectal cancer (CRC), sponsored by STCube. Primary endpoints: Dose-Limiting Toxicity at 6 months, Permanent discontinuation of IP due to adverse drug reactions at 6 months and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nelmastobart
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07656038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656038.